Publication Name	World Journal of Gastroenterology
Manuscript ID	33549
Country	Croatia

Received	2017-02-15 15:07
Peer-Review Started	2017-02-19 16:04
First Decision by Editorial Office Director
Return for Revision	2017-04-06 10:28
Revised	2017-05-03 22:27
Publication Fee Transferred
Second Decision by Editor	2017-06-27 06:07
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2017-07-04 05:52
Articles in Press	2017-07-04 05:52
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-07-31 09:22
Publish the Manuscript Online	2017-08-07 09:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
Manuscript Source	Invited Manuscript
All Author List	Domagoj Drmic, Danijela Kolenc, Spomenko Ilic, Lara Bauk, Marko Sever, Anita Zenko Sever, Kresimir Luetic, Jelena Suran, Sven Seiwerth and Predrag Sikiric
Funding Agency and Grant Number
Corresponding Author	Predrag Sikiric, MD, PhD, Professor, Departments of Pharmacology and Pathology, Medical Faculty University of Zagreb, Salata 11, POB 916, Zagreb 10000, Croatia. sikiric@mef.hr
Key Words	BPC 157; celecoxib; L-arginine; N(G)-nitro-L-arginine methyl ester; rats
Core Tip	In rats treated with the COX-2 inhibitor celecoxib, BPC 157 (given intraperitoneally) coun­teracted lesion development in the stomach, liver and brain. BPC 157 treatment alongside with N(G)-nitro-L-arginine methyl ester (L-NAME) also attenuated any effect of L-NAME that would otherwise have intensified the deleterious regular course. Consistently, with exacerbation (induced by L-NAME administration) and amelioration (due to L-arginine) of gastric, liver and brain lesions, L-arginine amelioration prevailed (i.e., the gastric, liver and brain lesions were attenuated) when given together with L-NAME (L-NAME + L-arginine), an effect further reversed toward a marked beneficial effect by the addition of BPC 157 (L-NAME + L-arginine + BPC 157).
Publish Date	2017-08-07 09:17
Citation	Drmic D, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwerth S, Sikiric P. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World J Gastroenterol 2017; 23(29): 5304-5312
URL	http://www.wjgnet.com/1007-9327/full/v23/i29/5304.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i29.5304

Full Article (PDF)	WJG-23-5304.pdf
Full Article (Word)	WJG-23-5304.doc